SWELTO - Space WEather Laboratory in Turin Observatory

SWELTO - Space WEather Laboratory in Turin Observatory is a conceptual framework where new ideas for the analysis of space-based and ground-based data are developed and tested. The input data are (but not limited to) remote sensing observations (EUV images of the solar disk, Visible Light coronagraphic images, radio dynamic spectra, etc...), in situ plasma measurements (interplanetary plasma density, velocity, magnetic field, etc...), as well as measurements acquired by local sensors and detectors (radio antenna, fluxgate magnetometer, full-sky cameras, located in OATo). The output products are automatic identification, tracking, and monitoring of solar stationary and dynamic features near the Sun (coronal holes, active regions, coronal mass ejections, etc...), and in the interplanetary medium (shocks, plasmoids, corotating interaction regions, etc...), as well as reconstructions of the interplanetary medium where solar disturbances may propagate from the Sun to the Earth and beyond. These are based both on empirical models and numerical MHD simulations. The aim of SWELTO is not only to test new data analysis methods for future application for Space Weather monitoring and prediction purposes, but also to procure, test and deploy new ground-based instrumentation to monitor the ionospheric and geomagnetic responses to solar activity. Moreover, people involved in SWELTO are active in outreach to disseminate the topics related with Space Weather to students and the general public

Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p

Endothelial dysfunction (ED) causes worse prognoses in heart failure (HF) patients treated with cardiac resynchronization therapy (CRTd). ED triggers the downregulation of microRNA-130 (miR-130a-5p), which targets endothelin-1 (ET-1). Thus, we evaluated ED and the response to CRTd by assessing miR-130a-5p and ET-1 serum levels. We designed a prospective multi-center study with a 1-year follow-up to evaluate ED, ET-1, and miR-130a-5p in CRTd patients with ED (ED-CRTd) vs. patients without ED (NED-CRTd). Clinical outcomes were CRTd response, HF hospitalization, cardiac death, and all-cause death. At 1-year follow-up, NED-CRTd (n = 541) vs. ED-CRTd (n = 326) patients showed better clinical statuses, lower serum values of B type natriuretic peptide (BNP: 266.25 ± 10.8 vs. 297.43 ± 16.22 pg/mL; p p p p p p < 0.05). Higher miR-130a-5p levels (HR 1.490, CI 95% [1.014–2.188]) significantly predicted CRTd response; the presence of hypertension (HR 0.818, CI 95% [0.669–0.999]), and displaying higher levels of ET-1 (HR 0.859, CI 98% [0.839–0.979]), lymphocytes (HR 0.820, CI 95% [0.758–0.987]), LVEF (HR 0.876, CI 95% [0.760–0.992]), and ED (HR 0.751, CI 95% [0.624–0.905]) predicted CRTd non-response. Higher serum miR-130a-5p levels (HR 0.332, CI 95% [0.347–0.804]) and use of ARNI (HR 0.319, CI 95% [0.310–0.572]) predicted lower risk of HF hospitalization, whereas hypertension (HR 1.818, CI 95% [1.720–2.907]), higher BNP levels (HR 1.210, CI 95% [1.000–1.401]), and presence of ED (HR 1.905, CI 95% [1.238–2.241]) predicted a higher risk of HF hospitalization. Hence, serum miR-130a-5p could identify different stages of ED and independently predict CRTd response, therefore representing a novel prognostic HF biomarker

Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p

: Endothelial dysfunction (ED) causes worse prognoses in heart failure (HF) patients treated with cardiac resynchronization therapy (CRTd). ED triggers the downregulation of microRNA-130 (miR-130a-5p), which targets endothelin-1 (ET-1). Thus, we evaluated ED and the response to CRTd by assessing miR-130a-5p and ET-1 serum levels. We designed a prospective multi-center study with a 1-year follow-up to evaluate ED, ET-1, and miR-130a-5p in CRTd patients with ED (ED-CRTd) vs. patients without ED (NED-CRTd). Clinical outcomes were CRTd response, HF hospitalization, cardiac death, and all-cause death. At 1-year follow-up, NED-CRTd (n = 541) vs. ED-CRTd (n = 326) patients showed better clinical statuses, lower serum values of B type natriuretic peptide (BNP: 266.25 ± 10.8 vs. 297.43 ± 16.22 pg/mL; p &lt; 0.05) and ET-1 (4.57 ± 0.17 vs. 5.41 ± 0.24 pmol/L; p &lt; 0.05), and higher values of miR-130a-5p (0.51 ± 0.029 vs. 0.41 ± 0.034 A.U; p &lt; 0.05). Compared with NED-CRTd patients, ED-CRTd patients were less likely to be CRTd responders (189 (58%) vs. 380 (70.2%); p &lt; 0.05) and had higher rates of HF hospitalization (115 (35.3%) vs. 154 (28.5%); p &lt; 0.05) and cardiac deaths (30 (9.2%) vs. 21 (3.9%); p &lt; 0.05). Higher miR-130a-5p levels (HR 1.490, CI 95% [1.014-2.188]) significantly predicted CRTd response; the presence of hypertension (HR 0.818, CI 95% [0.669-0.999]), and displaying higher levels of ET-1 (HR 0.859, CI 98% [0.839-0.979]), lymphocytes (HR 0.820, CI 95% [0.758-0.987]), LVEF (HR 0.876, CI 95% [0.760-0.992]), and ED (HR 0.751, CI 95% [0.624-0.905]) predicted CRTd non-response. Higher serum miR-130a-5p levels (HR 0.332, CI 95% [0.347-0.804]) and use of ARNI (HR 0.319, CI 95% [0.310-0.572]) predicted lower risk of HF hospitalization, whereas hypertension (HR 1.818, CI 95% [1.720-2.907]), higher BNP levels (HR 1.210, CI 95% [1.000-1.401]), and presence of ED (HR 1.905, CI 95% [1.238-2.241]) predicted a higher risk of HF hospitalization. Hence, serum miR-130a-5p could identify different stages of ED and independently predict CRTd response, therefore representing a novel prognostic HF biomarker

Challenges during Metis-Solar Orbiter commissioning phase

Metis is the visible light and UV light imaging coronagraph on board the ESA-NASA mission Solar Orbiter that has been launched February 10th, 2020, from Cape Canaveral. Scope of the mission is to study the Sun up close, taking high-resolution images of the Sun’s poles for the first time, and understanding the Sun-Earth connection. Metis coronagraph will image the solar corona in the linearly polarized broadband visible radiation and in the UV HI Ly-α line from 1.6 to 3 solar radii when at Solar Orbiter perihelion, providing a diagnostics, with unprecedented temporal coverage and spatial resolution, of the structures and dynamics of the full corona. Solar Orbiter commissioning phase big challenge was Covid-19 social distancing phase that affected the way commissioning of a spacecraft and its payload is typically done. Metis coronagraph on-board Solar Orbiter had its additional challenges: to wake up and check the performance of the optical, electrical and thermal subsystems, most of them unchecked since Metis delivery to spacecraft prime, Airbus, in May 2017. The roadmap to the fully commissioned coronagraph is here described throughout the steps from the software functional test, the switch on of the detectors of the two channels, UV and visible, to the optimization of the occulting system and the characterization of the instrumental stray light, one of the most challenging features in a coronagraph

In-flight optical performance assessment for the Metis solar coronagraph

Metis is a multi-wavelength coronagraph onboard the European Space Agency (ESA) Solar Orbiter mission. The instrument features an innovative instrument design conceived for simultaneously imaging the Sun's corona in the visible and ultraviolet range. The Metis visible channel employs broad-band, polarized imaging of the visible K-corona, while the UV one uses narrow-band imaging at the HI Lya, i.e. 121.6 nm. During the commissioning different acquisitions and activities, performed with both the Metis channels, have been carried out with the aim to check the functioning and the performance of the instrument. In particular, specific observations of stars have been devised to assess the optical alignment of the telescope and to derive the instrument optical parameters such as focal length, PSF and possibly check the optical distortion and the vignetting function. In this paper, the preliminary results obtained for the PSF of both channels and the determination of the scale for the visible channel will be described and discussed. The in-flight obtained data will be compared to those obtained on-ground during the calibration campaign